Andrew Miller

Strategies for the modulation of phase II metabolism in a series of PKCε inhibitors.

R. Heim, J. Abt, A. Termin, 2014, Bioorganic & medicinal chemistry letters.

Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis.

L. Settimo, A. Tanner, H. Twin, 2019, ACS medicinal chemistry letters.

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

David Bebbington, Michael O'Donnell, Damien Fraysse, 2009, Bioorganic & medicinal chemistry letters.

Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.

A. Tanner, H. Twin, J. Jiménez, 2011, Journal of medicinal chemistry.

Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases.

L. Settimo, A. Tanner, Jaclyn L Henderson, 2013, Journal of medicinal chemistry.

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

M. Mortimore, D. Kay, D. Bebbington, 2009, Bioorganic & medicinal chemistry letters.